Boryung exclusively to distribute a new peptic ulcer drug.

Published: 2005-06-09 06:56:00

Updated: 2005-06-09 06:56:00

Boryung made a technical licence agreement with UCB S.A, a Japanese subsidiary of UCB at Boryung building on June 3 for the exclusive distribution of Stogar, a new H2 receptor antagonist drug for the treatment of peptic ulcer.

It shows a sustained blocking activity against the gastric acid excretion, a protection of stomach lining and an enhancement of the blood circulation. It also revealed...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.